Short answer: A US clinic considering radiofrequency (RF) microneedling should treat the FDA’s October 15, 2025 safety communication as a prompt to review provider qualifications, patient discussions, device instructions and adverse-event reporting. The agency says serious complications have been reported with certain dermatologic and aesthetic uses. It does not say every RF procedure will cause harm, and it does not make a finding about any TUOKE product.
What the alert actually covers
RF microneedling uses small needle-like electrodes to deliver electrical energy into and beneath the skin, creating local heat. This is not a laser, intense pulsed light (IPL) or LED treatment: those use optical radiation, with different exposure and operating questions. The FDA reports burns, scarring, fat loss, disfigurement, nerve damage and cases requiring surgical repair or other medical intervention in connection with certain RF microneedling uses. Its evaluation is ongoing. A report is a safety signal, not an incidence rate or proof that all marketed devices have the same risk profile.
The agency describes RF microneedling as a medical procedure rather than an at-home cosmetic treatment. It advises patients to seek a licensed healthcare provider trained and experienced in the procedure, to ask which device will be used and to discuss benefits and risks of available options. The communication also says RF microneedling devices are Class II medical devices cleared through the 510(k) process and points to the FDA’s searchable 510(k) records. A clearance is tied to an identified device and indication; it should not be converted into a blanket promise of treatment success.
What an operator can do with this information
Before adding an RF microneedling service, document the exact model, its FDA record and indicated use, its current instructions for use, the intended user, and any training and maintenance obligations. The clinic should decide who is clinically responsible for screening, informed consent, treatment parameters and follow-up. Ask the supplier to explain how a software revision, needle assembly or accessory relates to the documentation supplied for the unit being purchased. That is a procurement question, not a claim that every variation needs a new clearance.
Patient-facing material should identify the procedure honestly. Calling RF microneedling simply a painless beauty facial can obscure the fact that needles penetrate the skin and heat is delivered beneath it. A useful consent discussion would address alternatives and material risks, including the complications the FDA has flagged, in language appropriate to the proposed treatment. Staff also need a process for escalating unexpected symptoms rather than assuming they are routine post-treatment effects. The FDA invites patients and professionals to report complications through its established channels.
Limits of the signal
This FDA communication is specific to RF microneedling used for dermatologic or aesthetic skin procedures. It should not be represented as an FDA warning about all optical aesthetic equipment, or as evidence that a competitor’s event involved TUOKE. It contains no comparative efficacy study and no denominator from which to calculate a complication rate. State practice requirements and patient-specific clinical judgments require qualified local advice. Buyers comparing energy-based technologies should keep RF, laser, IPL and LED specifications, evidence and intended uses separate.
For related procurement and safety analysis, browse the optical aesthetic equipment insights archive. This article is independent editorial information, not a listing or regulatory-status statement for a TUOKE device.
Source
- US FDA, Potential Risks with Certain Uses of RF Microneedling, issued October 15, 2025; reviewed October 13, 2026.